TW202523309A - 含有尿嘧啶衍生物之醫藥組合物 - Google Patents

含有尿嘧啶衍生物之醫藥組合物 Download PDF

Info

Publication number
TW202523309A
TW202523309A TW113137842A TW113137842A TW202523309A TW 202523309 A TW202523309 A TW 202523309A TW 113137842 A TW113137842 A TW 113137842A TW 113137842 A TW113137842 A TW 113137842A TW 202523309 A TW202523309 A TW 202523309A
Authority
TW
Taiwan
Prior art keywords
compound
cov
infection
sars
formula
Prior art date
Application number
TW113137842A
Other languages
English (en)
Chinese (zh)
Inventor
佐藤淳
芝山啓允
上原彰太
宇納佑斗
Original Assignee
日商塩野義製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商塩野義製藥股份有限公司 filed Critical 日商塩野義製藥股份有限公司
Publication of TW202523309A publication Critical patent/TW202523309A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW113137842A 2023-10-05 2024-10-04 含有尿嘧啶衍生物之醫藥組合物 TW202523309A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2023173420 2023-10-05
JP2023-173420 2023-10-05
JP2024096866 2024-06-14
JP2024-096866 2024-06-14

Publications (1)

Publication Number Publication Date
TW202523309A true TW202523309A (zh) 2025-06-16

Family

ID=93938355

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113137842A TW202523309A (zh) 2023-10-05 2024-10-04 含有尿嘧啶衍生物之醫藥組合物

Country Status (4)

Country Link
JP (2) JP7674711B1 (https=)
AU (1) AU2024307335A1 (https=)
TW (1) TW202523309A (https=)
WO (1) WO2025005306A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552872A1 (en) * 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
JP7624093B2 (ja) * 2022-04-08 2025-01-29 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物

Also Published As

Publication number Publication date
JP7674711B1 (ja) 2025-05-12
WO2025005306A1 (ja) 2025-01-02
AU2024307335A1 (en) 2026-04-16
JPWO2025005306A1 (https=) 2025-01-02
JP2025108531A (ja) 2025-07-23

Similar Documents

Publication Publication Date Title
JP7105430B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
JP7466731B2 (ja) トリアジン誘導体を含有する経口投与する製剤
TW202320793A (zh) 含有三嗪衍生物之醫藥組合物
JP7236065B1 (ja) トリアジン誘導体を含有する医薬組成物
JP7273455B1 (ja) 新型コロナウイルス感染症治療用医薬
JP2024178473A (ja) ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
WO2023095860A1 (ja) ３ｃｌプロテアーゼ阻害剤及びｃｏｖｉｄ－１９治療用薬剤を組み合わせることを特徴とするｃｏｖｉｄ－１９治療用医薬
JP7261529B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
CN116782904A (zh) 含有三嗪衍生物的医药组合物
JP7674711B1 (ja) ウラシル誘導体を含有する医薬組成物
JP7692546B1 (ja) ウラシル誘導体の製造方法
TWI916636B (zh) 新型冠狀病毒感染症治療用醫藥
US20260125365A1 (en) Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same
HK40081541A (en) Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same
HK40114521A (en) Pharmaceutical composition containing triazine derivative
HK40081541B (zh) 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
WO2025074997A1 (ja) ウイルス増殖阻害活性を有する縮合複素環誘導体およびそれらを含有する医薬組成物